Revvity, Inc. (NYSE:RVTY) Shares Purchased by National Bank of Canada FI

National Bank of Canada FI increased its position in shares of Revvity, Inc. (NYSE:RVTY - Free Report) by 6,177.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 32,896 shares of the company's stock after purchasing an additional 32,372 shares during the period. National Bank of Canada FI's holdings in Revvity were worth $3,672,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Victory Capital Management Inc. increased its position in shares of Revvity by 17.4% during the 4th quarter. Victory Capital Management Inc. now owns 70,250 shares of the company's stock worth $7,841,000 after purchasing an additional 10,390 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Revvity by 13.7% during the third quarter. JPMorgan Chase & Co. now owns 344,115 shares of the company's stock worth $43,961,000 after buying an additional 41,497 shares during the period. Contravisory Investment Management Inc. increased its position in shares of Revvity by 1,715.9% during the fourth quarter. Contravisory Investment Management Inc. now owns 69,186 shares of the company's stock valued at $7,722,000 after acquiring an additional 65,376 shares during the last quarter. FMR LLC raised its stake in shares of Revvity by 40.8% in the 3rd quarter. FMR LLC now owns 155,556 shares of the company's stock valued at $19,872,000 after acquiring an additional 45,040 shares during the period. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of Revvity by 87.0% in the 4th quarter. Janney Montgomery Scott LLC now owns 7,891 shares of the company's stock worth $881,000 after acquiring an additional 3,672 shares during the last quarter. 86.65% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Revvity Stock Performance

Shares of RVTY stock traded up $1.67 during mid-day trading on Friday, hitting $94.69. 2,420,772 shares of the stock were exchanged, compared to its average volume of 886,179. The stock's fifty day simple moving average is $109.12 and its two-hundred day simple moving average is $115.17. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. Revvity, Inc. has a 12-month low of $89.61 and a 12-month high of $129.50. The stock has a market capitalization of $11.38 billion, a price-to-earnings ratio of 42.84, a P/E/G ratio of 3.82 and a beta of 1.07.

Revvity (NYSE:RVTY - Get Free Report) last released its quarterly earnings results on Friday, January 31st. The company reported $1.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same quarter in the prior year, the firm posted $1.25 EPS. On average, analysts forecast that Revvity, Inc. will post 4.94 EPS for the current year.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Shareholders of record on Friday, April 18th will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.30%. The ex-dividend date of this dividend is Thursday, April 17th. Revvity's payout ratio is currently 12.67%.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Sanford C. Bernstein lowered Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 target price on the stock. in a research report on Friday, January 10th. KeyCorp lifted their target price on Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Barclays reduced their price target on shares of Revvity from $140.00 to $110.00 and set an "overweight" rating on the stock in a research report on Thursday. Raymond James reiterated an "outperform" rating and set a $145.00 target price (up from $140.00) on shares of Revvity in a report on Monday, February 3rd. Finally, Bank of America upgraded shares of Revvity from a "neutral" rating to a "buy" rating and set a $138.00 price target for the company in a research note on Friday, December 13th. Four analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $133.75.

Insider Buying and Selling at Revvity

In other news, insider Joel S. Goldberg sold 15,170 shares of the stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the completion of the sale, the insider now owns 33,400 shares in the company, valued at approximately $4,232,782. This represents a 31.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.68% of the stock is currently owned by company insiders.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.